Caption Management, LLC Nuvalent, Inc. Call Options Transaction History

Caption Management, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$67.44 - $112.17 $1.03 Million - $1.72 Million	15,300 Added 26.84%	72,300 $7.4 Million
Q2 2024 Aug 14, 2024	SELL	$62.76 - $81.61 $4.71 Million - $6.12 Million	-75,000 Reduced 56.82%	57,000 $4.32 Million
Q1 2024 May 15, 2024	BUY	$72.35 - $88.99 $1.95 Million - $2.4 Million	27,000 Added 25.71%	132,000 $9.91 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $4.45 Million - $8.43 Million	105,000 New	105,000 $7.73 Million
Q1 2023 May 15, 2023	BUY	$25.42 - $33.52 $2.72 Million - $3.59 Million	107,000 Added 48.64%	327,000 $8.53 Million
Q4 2022 Feb 14, 2023	BUY	$18.46 - $36.37 $4.06 Million - $8 Million	220,000 New	220,000 $6.55 Million

209

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.55B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.